Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.44 |
| ▸ | TLR2 | O60603 | 3/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21473675 | 0.94 | GLP1R (0.45) | GLP1RTLR2EPHX2FNTAFNTB | |
| SCHEMBL24937934 | 0.87 | GLP1R (0.47) | GLP1RTLR2FNTAFNTBMEN1 | |
| SCHEMBL21012244 | 0.85 | FNTA (0.47) | FNTAFNTBMEN1KMT2AGNAI3 | |
| SCHEMBL5065774 | 0.85 | FNTA (0.47) | FNTAFNTBMEN1KMT2AGNAI3 | |
| SCHEMBL13253388 | 0.85 | FNTA (0.47) | FNTAFNTBMEN1KMT2AGNAI3 | |
| SCHEMBL13253389 | 0.82 | FNTA (0.49) | FNTAFNTBMEN1KMT2AGNAI3 | |
| SCHEMBL16566153 | 0.78 | CNR1 (0.58) | MEN1KMT2AMAPT | |
| SCHEMBL18064494 | 0.78 | CNR1 (0.58) | MEN1KMT2AMAPT | |
| SCHEMBL24042511 | 0.77 | GLP1R (0.51) | GLP1RTLR2FNTAFNTBMEN1 | |
| SCHEMBL7865417 | 0.77 | PLA2G2A (0.55) | TLR2EPHX2FNTAFNTBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220031631-A1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | MODERNATX, INC. (US) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220031631-A1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | LIPA, HDLBP, PLTP | GLP1R 999/4885TLR2 2116/4885EPHX2 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.